Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Alnylam Pharmaceuticals and Merck & Co. have mutually agreed to terminate their July 2006 amended and restated agreement.
Subscribe to our email newsletter
As a result, Cambridge, Massachusetts-based Alnylam has rescinded all grants of its intellectual property related to current and future Merck development programs, including the partnership’s former co-development programs.
John Maraganore, president and CEO of Alnylam said: “It is fundamentally in our best interests to terminate our Merck collaboration. We wish our colleagues at Merck the best of luck in their efforts.”